-- Neil is a proven healthcare executive who has successfully brought
innovative drugs to market --
MEMPHIS, Tenn.--(BUSINESS WIRE)--Sep. 1, 2016--
GTx, Inc. (Nasdaq: GTXI) today announced that Garry A. Neil, M.D., Chief
Scientific Officer, Medgenics, Inc., has been appointed to the GTx, Inc.
Board of Directors. Dr. Neil brings significant medical and drug
development leadership to the GTx Board of Directors and a proven track
record of turning new science into breakthrough commercial products. Dr.
Neil will serve on both the Nominating & Governance and Scientific and
Spanning more than twenty years in the pharmaceutical industry, Dr. Neil
held a number of senior positions within Johnson & Johnson, Astra Merck
Inc., Astra Pharmaceuticals, AstraZeneca, and Merck KGaA. Dr. Neil is a
fellow of the American College of Physicians and the American College of
Gastroenterology, as well as a member of the American Association of
Immunologists and the Society for Clinical Trials.
“We are extremely pleased to have Garry join our Board of Directors;
under his leadership several important medicines for the treatment of
cancer, anemia, infections, central nervous system and psychiatric
disorders, pain, and genitourinary and gastrointestinal diseases gained
initial or expanded approvals,” said Dr. Robert J. Wills, Executive
Chairman of GTx. “Garry’s deep understanding of the needs of patients
will also be invaluable to our team as we focus on developing novel
targeted hormonal therapies to provide better medicines for patients.”
Since 2013, Dr. Neil has been the Chief Scientific Officer at Medgenics,
Inc., a gene therapy company focused on treating patients with rare
genetic and orphan diseases. Prior to Medgenics, he was a Partner and
the Head of R&D at Apple Tree Partners, a life sciences private equity
firm. From 2002 to 2012, Dr. Neil held various leadership positions
including Corporate Vice President of Science & Technology at Johnson &
Johnson, and Group President at Johnson & Johnson Pharmaceutical
Research and Development. Prior to joining Johnson & Johnson, he held
senior positions at Astra Merck, AstraZeneca, and EMD Pharmaceuticals.
Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D.
from the University of Saskatchewan College of Medicine. He completed
postdoctoral clinical training in internal medicine and gastroenterology
at the University of Toronto. He completed a postdoctoral research
fellowship at the Research Institute of Scripps Clinic. He held faculty
positions at the Ludwig Institute for Cancer Research, the University of
Iowa and the University of Pennsylvania (adjunct).
Dr. Neil serves on the Boards of Reagan-Udall Foundation and the
Foundation for the U.S. National Institutes of Health (NIH), and is a
past member of the Science Management Review Board of the NIH. He is
past Chairman of the Pharmaceutical Research and Manufacturers
Association (PhRMA) Science and Regulatory Executive Committee, the
PhRMA Foundation Board and he is the founding Chairman of TransCelerate
GTx, Inc., headquartered in Memphis, Tenn., is a
biopharmaceutical company dedicated to the discovery, development and
commercialization of small molecules for the treatment of cancer,
including treatments for breast and prostate cancer, and other serious
View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005172/en/
Source: GTx, Inc.
Lauren Crosby, 901-271-8622
Denise Powell, 510-703-9491